Essex Bio-Technology Limited

HKSE 1061.HK

Essex Bio-Technology Limited EBITDA for the year ending December 31, 2023: USD 53.56 M

Essex Bio-Technology Limited EBITDA is USD 53.56 M for the year ending December 31, 2023, a 33.46% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Essex Bio-Technology Limited EBITDA for the year ending December 31, 2022 was USD 40.14 M, a -28.32% change year over year.
Essex Bio-Technology Limited EBITDA for the year ending December 31, 2021 was USD 55.99 M, a 55.35% change year over year.
Essex Bio-Technology Limited EBITDA for the year ending December 31, 2020 was USD 36.04 M, a -27.26% change year over year.
Essex Bio-Technology Limited EBITDA for the year ending December 31, 2019 was USD 49.55 M, a 29.45% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

HKSE: 1061.HK

Essex Bio-Technology Limited

CEO	Dr. Mia Je Ngiam B.Sc.
IPO Date	June 27, 2001
Location	China
Headquarters	No. 88 Keji 6th Road
Employees	1,459
Sector	Consumer Discretionary
Industries Eyewear Biotechnology Cleaning Supplies Cosmetics Glass Personal Care Pharmaceuticals Plastics

Description

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and Yi Xue An Granules. It has license agreements with Mitotech S.A. and Mitotech LLC. The company was founded in 1990 and is headquartered in Zhuhai, China.

Key trends

Past 5 years